ZCCHC9

Across TCGA pan-cancer cohorts, ZCCHC9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZCCHC9 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZCCHC9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZCCHC9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LGG, and UCEC are the cancer types where ZCCHC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.128	0.710	.001	36	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.623	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZCCHC9–HNSC (DFS)

Open the HNSC breakdown →